ArticlePrzeglad gastroenterologiczny2024
Ophthalmological manifestations in inflammatory bowel disease under the watchful eye of a gastroenterologist from a tertiary centre.
Article in Przeglad gastroenterologiczny, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Ophthalmological manifestations (O-EIM) are one of the extraintestinal manifestations (EIM) of inflammatory bowel disease (IBD), although their frequency and potential relationship with disease activity and treatment remain underestimated. Aim: The aim of this screening questionnaire was to assess the number of EIM, including O-EIM, among patients with IBD. Material and methods: 436 patients with IBD and 102 patients without IBD were included in this single-centre retrospective study. The questionnaire consisted of questions regarding the frequency of EIM, including confirmed O-EIM and ophthalmological symptoms which had not been confirmed by an ophthalmologist. Results: EIM were present in 48.6% of cases; O-EIM were declared by 8.9% (uveitis 3.9% + episcleritis 4.8% + scleritis 0.2%) of the IBD patients. About half (50.7%) of them reported ophthalmological symptoms in the last 3 months, but only 30.5% reported consulting with an ophthalmologist. The multivariable logistic regression indicated some coexisting EIM (anaemia and axial/non-axial spondyloarthropathy), the use of certain medications (steroids, thiopurines, and methotrexate), smoking, family history of glaucoma, and spending more time in front of a computer screen as being linked with ophthalmological involvement among IBD patients. Conclusions: EIM, including O-EIM, are a common problem in patients with IBD. The presence of ophthalmological symptoms and the lack of follow-up with an ophthalmologist make it difficult to correctly estimate the true number of IBD patients experiencing O-EIM. Therefore, patients with IBD should be routinely referred for ophthalmological evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.